Letrozol Pharmakern (Letrozole)

Letrozol Pharmakern, an aromatase inhibitor, is used in several breast‑cancer treatment pathways.

• Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth.
• Adjuvant treatment of early breast cancer: lowers the risk of disease recurrence after surgery.
• Metastatic breast cancer: helps control disease progression and may extend survival.

• Letrozole selectively and non‑steroidally inhibits the aromatase enzyme, which converts adrenal androgens into estrogens in peripheral tissues. By blocking this conversion, systemic estrogen levels fall, depriving estrogen‑dependent tumor cells of a key growth stimulus and thereby slowing or halting tumor proliferation.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Hot flashes: sudden feeling of warmth and sweating.
• Joint pain: aching or stiffness in joints.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: feeling of queasiness or urge to vomit.
• Headache: mild to moderate head discomfort.
• Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Severe liver injury: marked elevation of liver enzymes or jaundice.
• Bone fracture: increased risk of osteoporosis‑related breaks.
• Pulmonary embolism: sudden shortness of breath and chest pain.
• Myocardial infarction: heart attack symptoms such as chest pressure.
• Anaphylaxis: rapid onset of allergic reaction with airway compromise.
• Elevated cholesterol: significant rise in blood lipid levels.

Patients should be monitored for specific safety concerns before and during therapy.

• Bone health monitoring: assess bone mineral density regularly.
• Liver function testing: check hepatic enzymes at baseline and periodically.
• Cardiovascular risk assessment: evaluate for hypertension, hyperlipidaemia, and thrombotic history.
• Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception in women of child‑bearing potential.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole may interact with other medicines that affect its metabolism or therapeutic outcomes.

Major Interactions (Avoid)

• Estrogen replacement therapy: may counteract letrozole’s estrogen‑lowering effect.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce plasma concentrations.
• Strong CYP2C19 inhibitors (e.g., fluconazole): may increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Statins: potential for increased muscle toxicity.
• SSRIs (e.g., fluoxetine): may modestly raise letrozole levels.
• Glucocorticoids: possible additive effects on bone loss.
• Oral contraceptives: generally ineffective in postmenopausal patients but may affect hormone balance if used off‑label.